MPI Research to assist Kineta in autoimmune drug development program

Oct 24 2009

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system. MPI Research will assist Kineta with advancing their promising autoimmune drug development program. This collaboration will enable phase one human trials to begin in 2010.

Dr. Tina Rogers, PhD, MBA, DABT, Director of Research and Executive Vice President at MPI Research, states, “We have a team of great scientists highly knowledgeable about autoimmune diseases and we are eager to collaborate with Kineta on their novel drug development program.” Kineta President and CEO, Charles L. Magness, PhD concurs and says, “Partnering with a progressive company such as MPI Research allows Kineta to creatively advance our program, accelerating progress of our lead autoimmune drug into man. We look forward to a strong collaboration focused on shared goals.”

http://www.mpiresearch.com/